The Present Clinical Treatment and Future Emerging Interdisciplinary for Heart Failure: Where we are and What we can do

被引:0
|
作者
Yu Yang
Jiamin Gao
Zhen Qin
Yongzheng Lu
Yanyan Xu
Jiacheng Guo
Xiaolin Cui
Jinying Zhang
Junnan Tang
机构
[1] The First Affiliated Hospital of Zhengzhou University,Department of Cardiology
[2] Henan Province Key Laboratory of Cardiac Injury and Repair,School of Medicine
[3] Henan Province Clinical Research Center for Cardiovascular Diseases,undefined
[4] The Chinese University of Hong Kong,undefined
来源
Intensive Care Research | 2023年 / 3卷 / 1期
关键词
Heart failure; Clinical Treatment; Interdisciplinary; Future Perspective;
D O I
10.1007/s44231-023-00029-4
中图分类号
学科分类号
摘要
Heart failure is a complex clinical syndrome caused by the progression to severe stages of various cardiac diseases, characterized by high morbidity and mortality. With the increasing aging of the population and the poor control of high-risk factors for heart failure such as hypertension and diabetes, the incidence of heart failure remains high. Therefore, there is widespread global attention regarding the various treatments for heart failure. Currently, pharmacological therapy, associated device therapy, interventional therapy, and end-stage surgical related therapy are the main clinical treatments for heart failure. Heart failure treatment is gradually evolving to be more precise, safe, and effective, as traditional therapies can no longer match clinical needs. A number of cutting-edge research studies are being conducted on the treatment of heart failure, based on the different pathogenesis and causes of heart failure, to treat patients with heart failure in a multifaceted and integrated way. This article summarizes the current clinical treatment of heart failure and the latest therapeutic advances in heart failure in current research to further promote the standardized management and treatment of heart failure and improve patient prognosis.
引用
收藏
页码:3 / 11
页数:8
相关论文
共 50 条
  • [21] Where should we go tomorrow? The Internet and what we can do with it
    Kornberg, C
    SPORTS EXERCISE AND INJURY, 1998, 4 (01): : 32 - 34
  • [22] Advanced heart failure: Where do we stand?
    Tousoulis, Dimitris
    HELLENIC JOURNAL OF CARDIOLOGY, 2019, 59 (06) : 303 - 305
  • [23] WHAT DO WE KNOW AND WHERE CAN WE GO - A SUMMARY AND A RESPONSE
    SCHULTZ, B
    ANDERSON, J
    AMERICAN BEHAVIORAL SCIENTIST, 1986, 29 (03) : 368 - 376
  • [24] Statins in Heart Failure—Where Do We Stand?
    Kristopher S. Lyons
    Gary E. McVeigh
    Mark T. Harbinson
    Cardiovascular Drugs and Therapy, 2011, 25 : 99 - 104
  • [25] Resistance in tuberculosis: what do we know and where can we go?
    Green, Keith D.
    Garneau-Tsodikova, Sylvie
    FRONTIERS IN MICROBIOLOGY, 2013, 4
  • [26] Bias and discrimination in surgery: Where are we and what can we do about it?
    Morrison, Zachary
    Perez, Numa
    Ahmad, Hira
    Utria, Alan
    McCulloh, Christopher
    Lopez, Monica
    Reyes-Ferral, Cynthia
    Newman, Erika
    Martin, Kathryn
    JOURNAL OF PEDIATRIC SURGERY, 2022, 57 (07) : 1315 - 1320
  • [27] Sublingual immunotherapy: where do we stand? Present and future
    Passalacqua, Giovanni
    Pawankar, Ruby
    Baena-Cagnani, Carlos E.
    Canonica, Giorgio Walter
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 9 (01) : 1 - 3
  • [28] The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?
    Selim, Ahmed
    Zolty, Ronald
    Chatzizisis, Yiannis S.
    PHARMACOLOGY & THERAPEUTICS, 2017, 178 : 67 - 82
  • [29] Where are we? What do we need?
    Karlsson, Jon
    Becker, Roland
    KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY, 2014, 22 (07) : 1465 - 1466
  • [30] Depression and heart disease: What do we know, and where are we headed?
    Pozuelo, Leo
    Zhang, Jianping
    Franco, Kathleen
    Tesar, George
    Penn, Marc
    Jiang, Wei
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2009, 76 (01) : 59 - 70